T<sub>H</sub>17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins

Moffitt, Kristin; Howard, A.; Martin, Sara; Cheung, Elaine; Herd, Muriel; Basset, A; Malley, Richard

doi:10.1128/cvi.00118-15

Cited by 14 publications

(16 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The current engineered whole‐cell pneumococci showed complete prevention of colonization in mice, which differs from that of Moffitt et al . () and Lu et al . ().…”

Section: Discussionmentioning

confidence: 91%

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The current engineered whole‐cell pneumococci showed complete prevention of colonization in mice, which differs from that of Moffitt et al . () and Lu et al . ().…”

Section: Discussionmentioning

confidence: 91%

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

et al. 2018

View full text Add to dashboard Cite

show abstract

“…In addition, a whole-cell vaccine against Streptococcus pneumoniae induces Th17 responses, allowing for protection against colonization. 73 If meningococcal vaccines elicit such responses, the protection against colonization would likely impact herd immunity.…”

Section: Discussionmentioning

confidence: 99%

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature

Balmer

Burman

Serra

et al. 2018

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Colonization of the human nasopharyngeal tract by the bacterium Neisseria meningitidis is usually asymptomatic, but life-threatening meningococcal disease with a clinical presentation of meningitis, septicemia, or more rarely, gastrointestinal symptoms, can develop. Invasive meningococcal disease (IMD) can be fatal within 24 hours, but IMD is vaccine-preventable. Vaccines used to protect against IMD caused by 5 of the 6 most common serogroups (A, B, C, W, and Y) may also influence carriage prevalence in vaccinated individuals. Lower carriage among vaccinated people may reduce transmission to nonvaccinated individuals to provide herd protection against IMD. This article reviews observational and clinical studies examining effects of vaccination on N. meningitidis carriage prevalence in the context of mass vaccination campaigns and routine immunization programs. Challenges associated with carriage studies are presented alongside considerations for design of future studies to assess the impact of vaccination on carriage.

show abstract

“…TLR2 is required for production of IL-17 by mucosal CD4 + T cells following IN vaccination and protection against different airway pathogens (Moffitt et al, 2014 , 2015 ). In addition, TLR4 enhances IL-17 responses following mucosal vaccination with nanoemulsion adjuvants (Bielinska et al, 2010 ).…”

Section: Discussionmentioning

confidence: 99%

Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice

Chuang

Pinn

Karakousis

et al. 2018

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb) remains a global health challenge due to the limited efficacy of the Mtb vaccine in current use, Bacillus Calmette–Guérin (BCG). To date, there is no available vaccine for immunocompromised individuals. Thus, there is an urgent need to develop a new vaccine candidate which can induce mucosal immunity in hosts with different immune statuses. DnaK (HSP70) has been shown to induce protective immunity against Mtb infection when administered by DNA vaccine; however, the protection is inferior to that induced by the BCG vaccine. In our study, we vaccinated C57BL/6J mice with DnaK protein alone. Subcutaneous or intranasal vaccination with DnaK generated IFNγ-secreting CD4+ T cells in the spleen, but only intranasal vaccination generated IL-17-releasing CD4+ T cells in the lungs, even when circulating CD4+ T cells were diminished. Furthermore, intranasal vaccination with DnaK generated tissue resident CD4+ T cells in the lungs. Vaccination with DnaK alone resulted in protective immunity comparable to BCG vaccination against tuberculosis in mice. Our results demonstrate that intranasal vaccination with DnaK can generate mucosal immunity in immunocompromised or immunocompetent mice and DnaK vaccination can generate protection against Mtb similar to BCG, underscoring its potential utility as an Mtb vaccine candidate in humans.

show abstract

T_H17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins

Cited by 14 publications

References 37 publications

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature

Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice

Contact Info

Product

Resources

About

TH17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins

Cited by 14 publications

References 37 publications

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

Construction and evaluation of a whole-cell pneumococcal vaccine candidate

Impact of meningococcal vaccination on carriage and disease transmission: A review of the literature

Intranasal Immunization with DnaK Protein Induces Protective Mucosal Immunity against Tuberculosis in CD4-Depleted Mice

Contact Info

Product

Resources

About

T_H17-Mediated Protection against Pneumococcal Carriage by a Whole-Cell Vaccine Is Dependent on Toll-Like Receptor 2 and Surface Lipoproteins